EGRX

Eagle Pharmaceuticals Inc
33.21
-0.54 (-1.6%)
Upgrade to Real-Time
Afterhours (Closed)
33.21
Volume 142,802
Bid Price 5.00
Ask Price 37.78
News -
Day High 33.57

Low
24.35

52 Week Range

High
53.78

Day Low 32.95
Company Name Stock Ticker Symbol Market Type
Eagle Pharmaceuticals Inc EGRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.54 -1.6% 33.21 20:00:00
Open Price Low Price High Price Close Price Prev Close
33.39 32.95 33.57 33.21 33.75
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,099 142,802 $ 33.25 $ 4,748,332 - 24.35 - 53.78
Last Trade Time Type Quantity Stock Price Currency
17:13:55 formt 57,415 $ 33.21 USD

Period:

Draw Mode:

Eagle Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 432.26M 13.02M 6.96M $ 171.55M $ 18.42M -0.66 20.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -461.00 14.30%

more financials information »

Eagle Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EGRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week33.6934.2231.7933.23131,403-0.48-1.42%
1 Month29.1834.2228.7532.06148,7884.0313.81%
3 Months32.4440.8527.970132.87153,6370.772.37%
6 Months39.7643.58624.3532.04165,211-6.55-16.47%
1 Year44.9553.7824.3538.30149,353-11.74-26.12%
3 Years55.7459.11524.3543.52140,386-22.53-40.42%
5 Years61.6385.6624.3550.42161,667-28.42-46.11%

Eagle Pharmaceuticals Description

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.